Search

Your search keyword '"Montrreal, L"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Montrreal, L" Remove constraint Author: "Montrreal, L"
44 results on '"Montrreal, L"'

Search Results

1. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8)

2. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

3. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

4. New insights into the genetic etiology of Alzheimer's disease and related dementias

5. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

6. New insights into the genetic etiology of Alzheimer's disease and related dementias

7. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

8. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

9. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

10. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

11. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE epsilon 4 Non-carriers

12. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ¿4 Non-carriers

13. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

14. Amyloid deposition in adults with drug-resistant temporal lobe epilepsy.

15. Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic.

16. Connecting genomic and proteomic signatures of amyloid burden in the brain.

17. Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer's disease spectrum.

18. The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in Alzheimer's disease.

19. An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response.

20. Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment.

21. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.

22. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort.

23. Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment.

24. Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults.

25. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment.

26. Mendelian Randomisation Confirms the Role of Y-Chromosome Loss in Alzheimer's Disease Aetiopathogenesis in Men.

27. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

28. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.

29. Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.

30. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.

31. Mitochondrial DNA and Alzheimer's disease: a first case-control study of the Tunisian population.

32. Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment.

33. Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.

34. Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort.

35. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

36. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis.

37. Long runs of homozygosity are associated with Alzheimer's disease.

39. Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic.

40. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.

41. Managing Clinical Trials for Alzheimer's Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain.

42. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers.

43. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.

44. Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes.

Catalog

Books, media, physical & digital resources